Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389796 | 1.00 | NOX4 (0.57) | NOX4CDK2ALDH3A1ALDH1A1MAPT | |
| SCHEMBL5316377 | 0.81 | POLB (0.53) | NOX4ALDH1A1MAPTTDP1KMT2A | |
| SCHEMBL29391103 | 0.81 | NOX4 (0.61) | NOX4ALDH1A1MAPTTDP1EGFR | |
| SCHEMBL607633 | 0.81 | NOX4 (0.61) | NOX4ALDH1A1MAPTTDP1EGFR | |
| SCHEMBL608266 | 0.81 | NOX4 (0.61) | NOX4ALDH1A1MAPTTDP1EGFR | |
| SCHEMBL609284 | 0.79 | MAPT (0.56) | NOX4CDK2ALDH1A1MAPTTDP1 | |
| SCHEMBL29390925 | 0.79 | MAPT (0.56) | NOX4CDK2ALDH1A1MAPTTDP1 | |
| SCHEMBL4093950 | 0.79 | NOX4 (0.59) | NOX4CDK2ALDH1A1MAPTTDP1 | |
| SCHEMBL608754 | 0.79 | NOX4 (0.61) | NOX4ALDH1A1MAPTTDP1EGFR | |
| SCHEMBL7095935 | 0.78 | ALDH1A1 (0.63) | ALDH3A1ALDH1A1MAPTTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | claimed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | claimed |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-07-27 | — | — | US | claimed |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | GNT PHARMA CO., LTD. (KR) | 2022-08-11 | — | — | US | claimed |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2022-08-04 | — | — | US | claimed |
| EP-3998058-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | GNT Pharma Co., Ltd (KR) | 2022-05-18 | — | — | EP | claimed |
| CN-114096227-A | Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof | 吉恩特药业株式会社 | 2022-02-25 | — | — | CN | claimed |
| CN-113710242-A | Compositions and methods for treating neurodegenerative disorders | 吉恩特药业株式会社 | 2021-11-26 | — | — | CN | claimed |
| EP-3902536-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT Pharma Co., Ltd (KR) | 2021-11-03 | — | — | EP | claimed |
| WO-2020136441-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | WO | claimed |
| EP-2004164-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2018-08-08 | — | — | EP | claimed |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | claimed |
| CN-103211824-A | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO LTD | 2013-07-24 | — | — | CN | claimed |
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | claimed |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-02-16 | — | — | US | claimed |
| CN-102316863-A | The medical usage of 5-benzylamino salicyclic acid derivatives or its salt | NEUROTECH PHARMACEUTICALS CO L | 2012-01-11 | — | — | CN | claimed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | claimed |
| CN-101426484-A | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD (KR) | 2009-05-06 | — | — | CN | claimed |
| EP-2004164-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | Neurotech Co., Ltd. (KR) | 2008-12-24 | — | — | EP | claimed |
| WO-2007119973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | HAO2, ACOX1, HAO1 | NOX4 195/4885CDK2 4386/4885ALDH3A1 612/4885 |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | NOX4 4612/4885CDK2 3143/4885ALDH3A1 1822/4885 |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | HTR5A, HTR6, MC5R | NOX4 1222/4885CDK2 4721/4885ALDH3A1 191/4885 |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | NOX4 1202/4885CDK2 1682/4885ALDH3A1 1685/4885 |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | NOX4 1202/4885CDK2 1682/4885ALDH3A1 1685/4885 |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | ALOX5, ALOX15, IL5 | NOX4 1921/4885CDK2 4115/4885ALDH3A1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.